| # | Aladdin ID | Assay Type | Description | Organism | Compounds | Reference | BAO Format | Source | |
|---|---|---|---|---|---|---|---|---|---|
| 1. | ALA3242311 | F | Antiinflammatory activity in mouse assessed as reduction of zymosan-induced number of neutrophils recovered from peritoneal exudates at 10 ng, iv administered 5 mins before zymosan challenge measured after 4 hrs by light microscopy/flow cytometry | Mus musculus | 2 | organism-based format | Scientific Literature | ||
| 2. | ALA3241216 | F | Antiinflammatory activity in mouse assessed as reduction of zymosan-induced neutrophil recruitment during peritonitis at 10 ng, iv administered 5 mins before zymosan challenge measured after 4 hrs by light microscopy/flow cytometry | Mus musculus | 2 | organism-based format | Scientific Literature | ||
| 3. | ALA3241217 | F | Pro-resolving activity in human macrophages assessed as increase of phagocytosis of fluorescence-labeled yeast cell wall particles at 100 nM to 10 pM preincubated for 15 mins measured after 60 mins | Homo sapiens | 2 | cell-based format | Scientific Literature | ||
| 4. | ALA3241218 | F | Pro-resolving activity in human macrophages assessed as increase of phagocytosis of bisbenzimide-labeled apoptotic neutrophils at 100 nM to 10 pM preincubated for 15 mins measured after 60 mins | Homo sapiens | 2 | cell-based format | Scientific Literature | ||
| 5. | ALA3383285 | F | Anti-inflammatory activity in FVB mouse with zymosan-induced sterile peritonitis assessed as reduction in PMN infiltration in peritoneal inflammatory exudates at 10 ng, ip measured at 4 hrs dosed 10 mins before zymosan challenge by light microscopy and flow cytometry | Mus musculus | 2 | organism-based format | Scientific Literature | ||
| 6. | ALA3383286 | F | Anti-inflammatory activity in FVB mouse with zymosan-induced sterile peritonitis assessed as reduction in PGD2 in peritoneal inflammatory exudates at 10 ng, ip dosed 10 mins before zymosan challenge by LC-MS/MS based targeted lipid mediator metabololipidomics | Mus musculus | 2 | organism-based format | Scientific Literature | ||
| 7. | ALA3383287 | F | Anti-inflammatory activity in FVB mouse with zymosan-induced sterile peritonitis assessed as reduction in PGF2alpha in peritoneal inflammatory exudates at 10 ng, ip dosed 10 mins before zymosan challenge by LC-MS/MS based targeted lipid mediator metabololipidomics | Mus musculus | 2 | organism-based format | Scientific Literature | ||
| 8. | ALA3383288 | F | Anti-inflammatory activity in FVB mouse with zymosan-induced sterile peritonitis assessed as reduction in TXB2 in peritoneal inflammatory exudates at 10 ng, ip dosed 10 mins before zymosan challenge by LC-MS/MS based targeted lipid mediator metabololipidomics | Mus musculus | 2 | organism-based format | Scientific Literature | ||
| 9. | ALA3383289 | F | Inhibition of LTB4-induced chemotaxis of human primary PMN at 0.01 to 100 nM pre-incubated for 10 mins followed by LTB4 stimulation by flow cytometry | Homo sapiens | 2 | assay format | Scientific Literature | ||
| 10. | ALA3383290 | F | Inhibition of IL8-induced chemotaxis of human primary PMN at 0.01 to 100 nM pre-incubated for 10 mins followed by IL8 stimulation by flow cytometry | Homo sapiens | 2 | assay format | Scientific Literature | ||
| 11. | ALA3383291 | F | Inhibition of LTB4-induced cell adhesion to fibronectin in human primary PMN at 0.1 to 10 nM pre-incubated for 10 mins followed by LTB4 stimulation by flow cytometry | Homo sapiens | 2 | assay format | Scientific Literature | ||
| 12. | ALA4416569 | A | Drug metabolism in human HepG2 cells assessed as 22-OH-NPD1 formation at 13 uM incubated for 4 hrs by RP-HPLC/MS analysis | Homo sapiens | 1 | cell-based format | Scientific Literature | ||
| 13. | ALA4416570 | A | Drug metabolism in human HepG2 cells assessed as (5Z,8R,9E,11E,13Z,15S,17Z)-8,15-Dihydroxyicosa-5,9,11,13,17-pentaenoic Acid formation at 13 uM incubated for 4 hrs by RP-HPLC/MS analysis | Homo sapiens | 1 | cell-based format | Scientific Literature | ||
| 14. | ALA4416571 | A | Drug metabolism in human HepG2 cells assessed as 3Z,6R,7E,9E,11Z,13S,15Z)-6,13-Dihydroxyoctadeca-3,7,9,11,15-pentaenoic Acid formation at 13 uM incubated for 4 hrs by RP-HPLC/MS analysis | Homo sapiens | 1 | cell-based format | Scientific Literature | ||
| 15. | ALA4416573 | A | Drug metabolism in human HepG2 cells assessed as 22-OH-NPD1 formation at 13 uM incubated for 4 hrs by tandem mass spectrometric analysis | Homo sapiens | 1 | cell-based format | Scientific Literature | ||
| 16. | ALA4416574 | A | Drug metabolism in human HepG2 cells assessed as (5Z,8R,9E,11E,13Z,15S,17Z)-8,15-Dihydroxyicosa-5,9,11,13,17-pentaenoic Acid formation at 13 uM incubated for 4 hrs by tandem mass spectrometric analysis | Homo sapiens | 1 | cell-based format | Scientific Literature | ||
| 17. | ALA4416575 | A | Drug metabolism in human HepG2 cells assessed as 3Z,6R,7E,9E,11Z,13S,15Z)-6,13-Dihydroxyoctadeca-3,7,9,11,15-pentaenoic Acid formation at 13 uM incubated for 4 hrs by tandem mass spectrometric analysis | Homo sapiens | 1 | cell-based format | Scientific Literature | ||
| 18. | ALA4416576 | A | Drug metabolism in human HepG2 cells treated with 13 uM Protectin-D1 assessed as compound formation incubated for 4 hrs by by tandem mass spectrometric analysis | Homo sapiens | 1 | cell-based format | Scientific Literature | ||
| 19. | ALA4416577 | A | Drug metabolism in human HepG2 cells assessed as (5Z,8R,9E,11E,13Z,15S,17Z)-8,15-Dihydroxyicosa-5,9,11,13,17-pentaenoic Acid formation at 13 uM after 30 mins by LC-MS/MS analysis | Homo sapiens | 1 | cell-based format | Scientific Literature | ||
| 20. | ALA4416578 | A | Drug metabolism in human HepG2 cells assessed as 3Z,6R,7E,9E,11Z,13S,15Z)-6,13-Dihydroxyoctadeca-3,7,9,11,15-pentaenoic Acid formation at 13 uM after 30 mins by LC-MS/MS analysis | Homo sapiens | 1 | cell-based format | Scientific Literature |
The page will load shortly, Thanks for your patience!